Pharmaceutical and diagnostics company Roche (SIX:RO) (OTCQX:RHHBY) stated on Tuesday that the US FDA EUA Elecsys Anti-SARS-CoV-2 antibody test is being used at more than 20 commercial and hospital lab sites throughout the US.
According to the company, it is working to meet demand by scaling global production rapidly in an effort to expand broader access as quickly as possible. It plans to increase to more than 200 commercial and hospital lab sites with the ability to perform two million tests per week. It has more than 3,000 analyzers that perform the antibody test installed across the US.
The company's Elecsys Anti-SARS-CoV-2 test, which is based on an in-solution double-antigen sandwich format, can detect antibodies to the new coronavirus causing COVID-19, which could signal whether a person has already been infected and potentially developed immunity to the virus. The Elecsys Anti-SARS-CoV-2 assay has 99.8% specificity and shows no cross-reactivity to the common cold, HIV and other coronaviruses. It can lower the chance of false positives due to the detection of similar antibodies that may be present in an individual.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT